Citigroup: Lowered Macau September gambling revenue forecast to 17 billion Macau patacas. It is reported that some tourists have postponed their trips until the National Day Golden Week.
Citigroup lowers its forecast for Macau's September gambling revenue from 17.75 billion to 17 billion Macau patacas.
Citibank released a research report stating that the gambling revenue in Macau for the first 22 days of September should reach 12.15 billion Macau Patacas, equivalent to 5.21 billion Macau Patacas per day, a weekly drop of about 3%. According to industry sources, the win rate in VIP rooms dropped by 11% to 13% compared to the previous period, while the win rate in mass market rooms dropped by 11% to 14%.
The bank pointed out that some tourists have delayed their trips to the National Day Golden Week, indicating that the gambling revenue in September may be lower than expected. The bank has lowered its forecast for Macau's gambling revenue in September from 17.75 billion to 17 billion Macau Patacas, representing a year-on-year increase of 14% or 77% compared to September 2019, reflecting the trends from the beginning of the month and the lower win rate in VIP rooms. This means that the remaining days of the month will have a daily gambling revenue of 6.06 billion Macau Patacas.
Related Articles

Henan Hengxing Science & Technology's subsidiary, Hengxing Chemical, was selected in the national-level list of "Little Giant" enterprises specializing in new technologies and products.

The $11.4 billion BD transaction validates the global innovation and commercialization potential, with INNOVENT BIO's (01801) valuation expected to increase.

Western: Accelerating progress in the nuclear fusion industry, with multiple technological pathways developing in parallel.
Henan Hengxing Science & Technology's subsidiary, Hengxing Chemical, was selected in the national-level list of "Little Giant" enterprises specializing in new technologies and products.

The $11.4 billion BD transaction validates the global innovation and commercialization potential, with INNOVENT BIO's (01801) valuation expected to increase.

Western: Accelerating progress in the nuclear fusion industry, with multiple technological pathways developing in parallel.

RECOMMEND

Why European Automakers Are Opposing Dutch Sanctions
20/10/2025

Domestic Commercial Rockets Enter Batch Launch Era: Behind the Scenes a Sixfold Cost Gap and Reusability as the Key Breakthrough
20/10/2025

Multiple Positive Catalysts Lift Tech Stocks; UBS Elevates China Tech to Most Attractive, Citing AI as Core Rationale
20/10/2025